12 / 17
Page 49
allied
academies
Journal of Medical Oncology & Therapeutics | Volume 4
March 18-19, 2019 | London, UK
Oncology & Cancer Therapy
International Conference on
Notes:
Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia
Lamia Ibrahim
Mansoura University, Egypt
A
cute myeloid leukemia (AML) represents a heterogeneous
group of malignancies with great variability in clinical course
and response to therapy. Several molecular markers have been
described that help to classify AML patients into risk groups.
Mutations in DNA methyltransferase 3A (DNMT3A) gene were
recently demonstrated inAML. Approximately 20%patientswith
AML carry DNMT3A gene mutations and were associated with
a poor clinical outcome but its clinical implications in Egyptian
AML patients are largely unknown.
The aimof the study
: was to study the incidence and prognostic
impact of DNMT3A mutations in patients with de novo acute
myeloid leukemia.
Subjects andmethods
: A total of 120 patients with de novo AML
were examined for mutations in DNMT3A by sequencing.
Results
: DNMT3A mutations were identified in 34/120 (28%)
of AML patients. 15 patients with M4, 14 patients with M5, 3
patient with M2 and 2 patient with M6. DNMT3A mutations
were more frequently associated with older age, higher platelet
counts and intermediate risk. DNMT3A-mutated patients did
not differ regarding complete remission (CR) and disease-free
survival (DFS), but had shorter overall survival (OS; P= 0.048)
than DNMT3A-wild-type patients. Mutations in DNMT3A
independently predicted a shorter OS (P = 0.049) bymultivariate
analysis.
Conclusion
: We concluded that DNMT3A mutations are highly
frequent in Egyptian patients with AML and are associated with
an unfavorable prognosis.
e:
loomy16@yahoo.com